Nuveen Asset Management LLC Has $23.73 Million Stock Holdings in Alphatec Holdings, Inc. (NASDAQ:ATEC)

Nuveen Asset Management LLC boosted its holdings in Alphatec Holdings, Inc. (NASDAQ:ATEC - Free Report) by 78.4% during the 4th quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm owned 2,584,996 shares of the medical technology company's stock after buying an additional 1,136,330 shares during the period. Nuveen Asset Management LLC owned approximately 1.82% of Alphatec worth $23,730,000 as of its most recent SEC filing.

Several other hedge funds also recently modified their holdings of the business. Vanguard Group Inc. lifted its holdings in shares of Alphatec by 0.8% during the 4th quarter. Vanguard Group Inc. now owns 5,968,980 shares of the medical technology company's stock worth $54,795,000 after acquiring an additional 47,797 shares during the period. American Century Companies Inc. grew its stake in shares of Alphatec by 36.5% in the 4th quarter. American Century Companies Inc. now owns 4,989,057 shares of the medical technology company's stock valued at $45,800,000 after purchasing an additional 1,334,780 shares during the period. Geode Capital Management LLC raised its holdings in shares of Alphatec by 1.0% in the 4th quarter. Geode Capital Management LLC now owns 2,387,162 shares of the medical technology company's stock worth $21,919,000 after buying an additional 24,283 shares in the last quarter. Marshall Wace LLP lifted its position in shares of Alphatec by 139.2% during the 4th quarter. Marshall Wace LLP now owns 1,773,246 shares of the medical technology company's stock worth $16,278,000 after buying an additional 1,032,070 shares during the period. Finally, Penn Capital Management Company LLC boosted its stake in Alphatec by 17.5% in the 4th quarter. Penn Capital Management Company LLC now owns 1,535,182 shares of the medical technology company's stock valued at $14,093,000 after buying an additional 228,933 shares in the last quarter. 66.35% of the stock is owned by institutional investors.

Insiders Place Their Bets

In related news, CEO Patrick Miles sold 12,691 shares of the stock in a transaction on Friday, March 7th. The shares were sold at an average price of $10.64, for a total transaction of $135,032.24. Following the completion of the transaction, the chief executive officer now owns 5,857,603 shares in the company, valued at approximately $62,324,895.92. This represents a 0.22% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, COO Scott Lish sold 55,375 shares of the business's stock in a transaction that occurred on Monday, May 19th. The stock was sold at an average price of $13.00, for a total value of $719,875.00. Following the transaction, the chief operating officer now directly owns 771,645 shares in the company, valued at $10,031,385. This trade represents a 6.70% decrease in their position. The disclosure for this sale can be found here. Over the last ninety days, insiders have sold 136,981 shares of company stock worth $1,644,556. Corporate insiders own 20.90% of the company's stock.

Alphatec Trading Down 0.7%

Shares of ATEC traded down $0.09 during trading hours on Wednesday, hitting $12.23. 170,302 shares of the stock traded hands, compared to its average volume of 2,026,701. The firm has a market capitalization of $1.79 billion, a PE ratio of -9.56 and a beta of 1.06. The company has a current ratio of 2.32, a quick ratio of 1.15 and a debt-to-equity ratio of 30.21. Alphatec Holdings, Inc. has a 1-year low of $4.88 and a 1-year high of $13.14. The business has a fifty day moving average of $11.16 and a 200-day moving average of $10.58.

Alphatec (NASDAQ:ATEC - Get Free Report) last posted its earnings results on Thursday, May 1st. The medical technology company reported ($0.35) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.12) by ($0.23). Alphatec had a negative return on equity of 541.39% and a negative net margin of 31.06%. The company had revenue of $169.18 million for the quarter, compared to analyst estimates of $167.57 million. During the same quarter in the previous year, the firm posted ($0.34) earnings per share. Alphatec's quarterly revenue was up 22.2% compared to the same quarter last year. Analysts expect that Alphatec Holdings, Inc. will post -1.08 EPS for the current year.

Wall Street Analysts Forecast Growth

ATEC has been the subject of several recent analyst reports. HC Wainwright reiterated a "buy" rating and set a $20.00 price objective on shares of Alphatec in a research note on Monday, April 14th. Wall Street Zen upgraded shares of Alphatec from a "sell" rating to a "hold" rating in a research report on Friday, February 28th. Needham & Company LLC restated a "buy" rating and issued a $16.00 price target on shares of Alphatec in a research report on Friday, May 2nd. Finally, Piper Sandler reiterated an "overweight" rating and issued a $15.00 target price (up previously from $13.00) on shares of Alphatec in a research note on Friday, May 2nd. Two research analysts have rated the stock with a hold rating and eight have issued a buy rating to the company. Based on data from MarketBeat, the company presently has a consensus rating of "Moderate Buy" and an average target price of $17.89.

Alphatec Company Profile

Alphatec Holdings, Inc, a medical technology company, designs, develops, and advances technologies for the surgical treatment of spinal disorders in the United States and internationally. It manufactures and sells implants and instruments through third-party suppliers. The company offers Alpha InformatiX product platform, including EOS imaging system that provides full-body imaging; VEA alignment mobile application, which leverages EOS technology to more quickly quantify alignment parameters on a mobile device; SafeOp Neural InformatiX System that automates electromyographic and somatosensory evoked potential monitoring; and Valence, an intra-operative system that integrates navigation and robotics into spine procedures, as well as Sigma Prone TransPsoas (PTP) Access and PTP Patient Positioning Systems.